secwatch.observer — SEC 8-K summary
======================================

Issuer:     Disc Medicine, Inc. (IRON)
CIK:        0001816736
Form:       8-K
Filed at:   2022-02-28T23:59:59+00:00
Accession:  0001193125-22-055899
Event type: other_material
Sentiment:  negative
Materiality: 0.80
Item codes: 2.05, 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Gemini cuts workforce ~80%, initiates strategic review; CEO departs
-------------------------------------------------------------------

- Workforce reduction of 24 employees (approx. 80%) by end of Q2 2022; restructuring charge $1.6-1.9M in Q1 2022.
- CEO Jason Meyenburg departs; Executive Chair Georges Gemayel appointed interim President and CEO.
- Company initiates strategic alternatives review to maximize shareholder value; no timetable set.
- Remaining employees to focus on GEM307 IND-enabling tasks.
- Separation agreement includes 12 months base salary, pro-rata bonus, COBRA, and continued equity vesting.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1816736/000119312522055899/0001193125-22-055899-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1816736/000119312522055899/d29362d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-22-055899

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer